tetano
Editor, Senior Moderator
Antimicrob Agents Chemother. 2018 Aug 27. pii: AAC.00694-18. doi: 10.1128/AAC.00694-18. [Epub ahead of print]
[h=1]Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.[/h] Ali SO[SUP]1[/SUP], Takas T[SUP]2[/SUP], Nyborg A[SUP]2[/SUP], Shoemaker K[SUP]2[/SUP], Kallewaard NL[SUP]2[/SUP], Chiong R[SUP]3[/SUP], Dubovsky F[SUP]2[/SUP], Mallory RM[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] We evaluated MEDI8852, a human IgG1 monoclonal antibody that binds a highly conserved influenza A hemagglutinin stalk epitope, in outpatients with uncomplicated influenza A infection. One hundred twenty-six subjects aged 18-65 years were enrolled during the 2015-2016 Northern and 2016 Southern Hemisphere seasons. Subjects with symptom onset ≤5 days before dosing were randomized to four cohorts: 750 mg (cohort 1) or 3,000 mg (cohort 2) MEDI8852 (single intravenous infusion) + 75 mg oseltamivir, placebo + 75 mg oseltamivir (cohort 3), and 3,000 mg MEDI8852 alone (cohort 4). Subjects were followed through day 10 for solicited influenza symptoms, day 28 for adverse events (AEs), and day 101 for serious AEs and AEs of special interest. Nasopharyngeal samples were collected through day 7 for confirmation of influenza A infection, viral shedding, and oseltamivir and MEDI8852 susceptibility. Slightly more AEs were reported in subjects receiving MEDI8852 (cohorts 1, 2, and 4 combined: 39/93, 41.9%) than oseltamivir only (cohort 3: 10/32, 31.3%). Most AEs were mild or moderate. The most common AE was bronchitis (11/93, 11.8%; 1/32, 3.1%). Median (range) decrease in viral shedding (log[SUB]10[/SUB] virus genome copies/mL) was similar between the two groups (-3.58 [-6.2. 0.5]; -3.43 [-5.9, 0.9]). Genotypic analyses found a limited number of hemagglutinin and neuraminidase amino acid changes between viruses isolated before and after therapy; however, none appeared within a known oseltamivir-resistant site or MEDI8852-binding region. The safety profile of MEDI8852 supports its continued development for treatment of patients hospitalized with influenza A infection.
PMID: 30150460 DOI: 10.1128/AAC.00694-18
[h=1]Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.[/h] Ali SO[SUP]1[/SUP], Takas T[SUP]2[/SUP], Nyborg A[SUP]2[/SUP], Shoemaker K[SUP]2[/SUP], Kallewaard NL[SUP]2[/SUP], Chiong R[SUP]3[/SUP], Dubovsky F[SUP]2[/SUP], Mallory RM[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] We evaluated MEDI8852, a human IgG1 monoclonal antibody that binds a highly conserved influenza A hemagglutinin stalk epitope, in outpatients with uncomplicated influenza A infection. One hundred twenty-six subjects aged 18-65 years were enrolled during the 2015-2016 Northern and 2016 Southern Hemisphere seasons. Subjects with symptom onset ≤5 days before dosing were randomized to four cohorts: 750 mg (cohort 1) or 3,000 mg (cohort 2) MEDI8852 (single intravenous infusion) + 75 mg oseltamivir, placebo + 75 mg oseltamivir (cohort 3), and 3,000 mg MEDI8852 alone (cohort 4). Subjects were followed through day 10 for solicited influenza symptoms, day 28 for adverse events (AEs), and day 101 for serious AEs and AEs of special interest. Nasopharyngeal samples were collected through day 7 for confirmation of influenza A infection, viral shedding, and oseltamivir and MEDI8852 susceptibility. Slightly more AEs were reported in subjects receiving MEDI8852 (cohorts 1, 2, and 4 combined: 39/93, 41.9%) than oseltamivir only (cohort 3: 10/32, 31.3%). Most AEs were mild or moderate. The most common AE was bronchitis (11/93, 11.8%; 1/32, 3.1%). Median (range) decrease in viral shedding (log[SUB]10[/SUB] virus genome copies/mL) was similar between the two groups (-3.58 [-6.2. 0.5]; -3.43 [-5.9, 0.9]). Genotypic analyses found a limited number of hemagglutinin and neuraminidase amino acid changes between viruses isolated before and after therapy; however, none appeared within a known oseltamivir-resistant site or MEDI8852-binding region. The safety profile of MEDI8852 supports its continued development for treatment of patients hospitalized with influenza A infection.
PMID: 30150460 DOI: 10.1128/AAC.00694-18